NCT06351644 ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Status TERMINATED Phase PHASE1/PHASE2
NCT06350565 A Clinical Pharmacological Study of Dose Halving of Dexamethasone in Pregnant Women With Preterm Labour With Preterm Birth at Greater Than or Equal to 34 Gestational Weeks (34GW+) Status NOT_YET_RECRUITING Phase NA
NCT06348147 Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation Status SUSPENDED Phase PHASE2
NCT06348108 Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma Status RECRUITING Phase PHASE1
NCT06342466 Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis Status RECRUITING Phase PHASE2
NCT06317662 Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia Status RECRUITING Phase PHASE2
NCT06300099 Dexamethasone Versus Dexmedetomidine as Adjuncts to Serratus Anterior Plane Block Status NOT_YET_RECRUITING Phase PHASE4
NCT06289673 Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma Status RECRUITING Phase PHASE4
NCT06288035 Oral Dexamethasone for Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy Status RECRUITING Phase PHASE3
NCT06269900 Dexamethasone for Treating Severe Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype Status RECRUITING Phase PHASE3
NCT06268704 Particulate vs. Non-Particulate Steroid for Sacroiliac Joint Injection Status RECRUITING Phase PHASE4
NCT06233604 Dexamethasone vs. Dexmedetomidine for ESPB in Pain Management After Hip Arthroplasty Status RECRUITING Phase PHASE4
NCT06233565 Dexamethasone vs. Dexmedetomidine for Popliteal Nerve Block in Pain Management After Pediatric Ankle and Foot Surgery Status COMPLETED Phase PHASE4
NCT06232707 A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Status WITHDRAWN Phase PHASE3
NCT06232044 Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma Status RECRUITING Phase PHASE1/PHASE2
NCT06230224 A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT06216158 Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma Status RECRUITING Phase PHASE3